Andrew P. Han

Though the funding is technically there, doctors may not be comfortable ordering the test and hospitals may wonder if they'll lose money from it.

The firm also spoke about the need to interact with the FDA to clarify how to get its SomaSignal assay for cardiovascular events into clinical trials.

By the end of the year, SomaLogic plans to add 10 more SomaScan diagnostic assays, CEO Roy Smythe told investors, bringing the total to around 30 assays.

Both suits referenced a recent story in the New York Times about poor NIPT performance for rarer chromosomal abnormalities, especially microdeletions.

Illumina is seeing continued strength in its core next-generation sequencing business as the firm is officially bringing Grail on board.

The FTC claimed that Illumina can and will disadvantage Grail's rivals, but lawyers for the companies said the merger's benefits outweigh "speculative harms."

Illumina faces potential fines in Europe for moving ahead with the deal but felt it had to act now in order to make sure it went through at all.

The company raised $60 million last week and will use the funding to develop and validate its DNA methylation-based tests and classifier algorithm.

The San Diego-based firm also said it expects European customers to get optical genome mapping-based assays for leukemia and FSHD accredited.

The clinical whole-genome sequencing and analysis firm is planning to add Oxford Nanopore long-read sequencing to all samples by the end of the year.